Patent Docs: If Patents Become Irrelevant in a Biosimilars Future, What About University Patents and Startups?

By Kevin E. Noonan -- The pros and cons of patenting in the biosimilars scheme recently enacted as part of the Patient Protection and Affordable Care Act have been discussed, here and elsewhere (see "Will Patents Become Irrelevant in a Biosimilars Future?"). Whether envisioned by the bill's drafters or not, the provisions of the Biologics Price Competition and Innovation Act of 2009...